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Abstract
Children diagnosed with the hereditary form of retinoblastoma (Rb), a rare eye cancer caused by a germline
mutation in the RB1 tumor suppressor gene, have excellent survival, but face an increased risk of bone and soft
tissue sarcomas. This predisposition to sarcomas has been attributed to genetic susceptibility due to inactivation of
the RB1 gene as well as past radiotherapy for Rb. The majority of bone and soft tissue sarcomas among hereditary
Rb survivors occur in the head, within the radiation field, but they also occur outside the radiation field. Sarcomas
account for almost half of the second primary cancers in hereditary Rb survivors, but they are very rare following
non-hereditary Rb. Sarcomas among hereditary Rb survivors arise at ages similar to the pattern of occurrence in the
general population. There has been a trend over the past two decades to replace radiotherapy with chemotherapy
and other focal therapies (laser or cryosurgery), and most recently, chemosurgery in order to reduce the incidence
of sarcomas and other second cancers in Rb survivors. Given the excellent survival of most Rb patients treated in
the past, it is important for survivors, their families and health care providers to be aware of the heightened risk for
sarcomas in hereditary patients.
Keywords: Retinoblastoma, Soft tissue sarcoma, Bone sarcoma, Radiotherapy, Epidemiology, RB1 gene, Hereditary
Introduction
Children diagnosed with the hereditary form of retino-
blastoma (Rb), a rare eye cancer caused by a germline
mutation in the RB1 tumor suppressor gene, have excel-
lent survival, but face an increased risk for the develop-
ment of sarcomas, both soft tissue (STS) and bone. This
predisposition to sarcomas in retinoblastoma survivors
has been attributed to genetic susceptibility as well as
past radiation treatment for Rb.
Retinoblastoma epidemiology
Retinoblastoma is a rare pediatric cancer of the eye with
an autosomal dominant inheritance pattern. It is caused
by mutations in the RB1 tumor suppressor gene, located
on chromosome 13q14 with very high penetrance and
expressivity [1]. Approximately 80%-90% of RB1 gene
carriers develop ocular tumors. This gene encodes the
cell cycle regulatory retinoblastoma gene protein (pRb),
controls cellular differentiation during both embryogen-
esis and in adult tissues, regulates apoptotic cell death,
maintains cell cycle arrest and preserves chromosome
stability [2].
Retinoblastoma occurs in two forms: hereditary (30-40%)
and non-hereditary (60-70%). Hereditary retinoblastoma is
caused by a germline mutation in one allele of the RB1
gene and an acquired somatic mutation in the other allele,
whereas the non-hereditary form is caused by somatic
mutations in both alleles. The hereditary form is character-
ized by disease in both eyes (bilateral Rb) and is typically
diagnosed before 12 months of age, whereas, the non-
hereditary form affects one eye (unilateral Rb) and is diag-
nosed between 2–5 years of age. About 10-15% of patients
with unilateral Rb, however, carry a germline mutation and
are considered hereditary. This difference in diagnosis age
led Knudson to develop the two-hit theory [3], in which
only one additional mutation is needed for hereditary Rb
and two hits or somatic mutations are needed for non-
hereditary Rb [4]. The age-adjusted annual incidence rate
of retinoblastoma is 3.1 per 107 with a 5-year relative sur-
vival of 97.5% in the U.S. [5]. Treatment for Rb has historic-
ally consisted primarily of radiotherapy (both external
beam and radioactive plaques), enucleation, chemotherapy,
focal therapies such as laser or cryotherapy, or a combin-
ation of these modalities.
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Subsequent malignancies after retinoblastoma
Long-term survivors of hereditary retinoblastoma are at an
increased 20-fold risk of developing and dying from a sub-
sequent non-ocular cancer, primarily bone and soft tissue
sarcomas, melanoma and brain tumors [6,7]. Survivors of
non-hereditary Rb are at much lower risk of a subsequent
primary cancer, similar to the risk in the general population
[8-10]. The risk for sarcomas in hereditary patients has
been attributed to genetic susceptibility and past treatment
with radiation [8,11,12]. In addition to radiotherapy,
chemotherapy, specifically alkylating agents, has been asso-
ciated with the risk of bone cancer after Rb [6,13,14], but
less so for soft tissue sarcomas [15].
Bone sarcomas after retinoblastoma
Patterns of risk
Bone sarcomas are one of the most common second pri-
mary cancers occurring after hereditary retinoblastoma
accounting for 25%-30% of all second primary cancers
[6-8,16,17]. Bone sarcomas are typically diagnosed in Rb
survivors between 10 and 20 years of age, similar to the
incidence pattern in the general population [5]. In these
studies, the majority of bone sarcomas occurred within
the radiation field in the head region, but up to 40% was
diagnosed outside the treatment field, primarily in the
lower legs [8,11,17].
Table 1 presents risks for bone sarcomas from epi-
demiologic cohort studies including at least 100 her-
editary Rb survivors. The standardized incidence and
mortality rates for bone sarcomas are increased sev-
eral hundred-fold compared to population rates, due to
the rarity of these tumors in the general population. A
much lower risk for bone sarcomas was observed in the
one cohort study that included non-irradiated survivors
and began follow-up 25 years after Rb diagnosis [10]. It
has been estimated that the cumulative incidence of bone
sarcoma following retinoblastoma is 7% at 20 years
[13,18]. Osteosarcoma is the most common type of bone
sarcoma reported after Rb, but both chondrosarcoma and
Ewing sarcoma have been reported as well [19,20], al-
though risk estimates are not available for these other two
types.
Treatment for Rb and risk of bone sarcomas
Both high-dose radiation and increasing cumulative dose
of chemotherapy, mainly alkylating agents (cyclophos-
phamide and triethylenemelamine or TEM), have been
linked to the occurrence of bone sarcomas following
hereditary Rb [13,14]. Higher risks have been noted for
the combination of radiotherapy and chemotherapy
compared to either treatment alone [6-8,13,14]. An earl-
ier study of British Rb patients provided some evidence
that cyclophosphamide may increase the effect of radio-
therapy on the risk of bone sarcoma [8].
In a case–control study of bone and soft tissue sarcomas
after hereditary Rb, risk increased with increasing dose up
to 10.7-fold at doses greater than 60 Gy [11]. The mean
dose to the head among cases was 32.8 Gy, whereas the
lower limbs had received virtually no radiation (<0.1 Gy).
In an update of that study, the location of 75 bone sarco-
mas was skull and face (61%), lower limbs (29%), trunk
(7.6%), and unknown location (3.8%) [7].
Based on a series of 155 osteosarcomas following heredi-
tary Rb identified from the literature and one institute,
investigators reported that the mean age of onset was
related to the osteosarcoma location [21]. Sarcomas occur-
ring in the radiation field were diagnosed one year earlier
compared to those diagnosed outside the field (mean
age=12.2 years [range 3–35] vs. mean age = 13.4 years
[range 4–22]. This age difference suggested to the investi-
gators that different biologic mechanisms may be asso-
ciated with the development of bone sarcomas depending
upon the location in the body.
Studies of other pediatric malignancies have also
reported an increased risk for second osteosarcomas fol-
lowing radiation and chemotherapy treatment for a first
cancer (for a detailed review of radiation-related sarcomas,
see Berrington de Gonzalez et al. in this issue).
Soft Tissue Sarcomas
Patterns of risk
Soft tissue sarcomas (STS) are also one of the most
common subsequent cancers following hereditary Rb
accounting for 12% up to 32% of all second cancers
[6,7,16]. In one large cohort study, an increased risk for
STS was first observed within 10 years of Rb diagnosis
and continued through adult life up to 50 years after Rb,
with specific subtypes occurring at similar ages as in the
general population [22,23]. Fifty years after radiation
treatment for hereditary Rb, the cumulative risk of
developing a STS was 13.1%, and the cumulative inci-
dence for a STS inside the radiation field was higher
than outside the field (8.9% vs. 5.1%) [22]. Table 2 pre-
sents the incidence and mortality due to STS after Rb in
cohort studies of at least 100 hereditary Rb survivors.
Subtype heterogeneity
STS diagnosed in Rb patients comprise a heterogeneous
group of tumors of fat, cartilage and muscle; however,
only one study has evaluated the risk of STS by histology
after hereditary Rb [22]. Leiomyosarcoma (LMS) consti-
tuted the most common type of STS after Rb, with the
majority diagnosed 30 and more years after Rb. This is
consistent with LMS being one of the most common
STS in the general population [23]. Although many LMS
occurred in the head and neck region, the majority of
LMS in females were diagnosed in the uterus [24]. Loss
of heterozygosity in RB1 has been reported in uterine
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Table 1 Summary of bone sarcoma after retinoblastoma in cohort studies of 100 or more hereditary retinoblastoma survivors














Kleinerman 2005 [7] US
Two US medical centers
Hospital-based
1914-1984
963 1-yr survivors Mean: 25 75 360 (283–451) Any radiation: 406 (318–511)











NA*, 5-yr survivors Mean: 26 35 289 (209–402) NA AER= 23; * No. of Rb survivors
not given but there are estimated
to be 809 hereditary Rb subjects
based on MacCarthy et al. [44]





298 survivors Median: 22 16 314 (180–511) Radiation only: 302 (130–596)
Radiation + chemotherapy:
586 (215–1275); Surgery only:
75 (1.9-421)
AER= 23
Tucker 1987 [14] US
Late Effects Study Group
Hospital-based
1945-1979
319 2-yr survivors Mean: 7 12 999 (515–1745) *Hereditability not specified
1b. Mortality SMR, 95%CI SMR by treatment for
retinoblastoma




1092 1-yr survivors Median: 29 56 595 (449–773) Radiation: 673 (506–879) AER= 19.8; *No difference between
males and females




337 (alive in 1961) Median: 26 yr
Follow-up
1961-2005
11 289 (144–517) Radiation only: 266 (72.2-680)
Radiation + chemotherapy:
659 (179–1686); Surgery only:
124 (15–449)
Majority deaths from bone cancer
occur within first 30 years




408 Median: 11 9 392 (204-753) NA
Fletcher 2004 [10] Patients
from British hospitals and
linkage with national registry
Hospital-based
1873-1950
144 25-yr survivors Follow up began
in 1940
Median age: 60
1 32.4 (0.82 - 180) NA *Radiation was not typically used
to treat Rb during these years



















Table 2 Summary of soft tissue sarcoma after retinoblastoma in cohort studies of 100 or more hereditary retinoblastoma survivors


















963 1-yr survivors Mean: 25 69 184 (143–233) Any radiation: 212 (164–270);




AER=27 *No evidence of risk
modification by sex *SIRs highest
within first 10 years but remained
significantly elevated ≥30





NA, 5-yr survivors Mean: 26 16 N/A N/A Rates increase over time since Rb
(highest >25)








AER=29; SIRs elevated in all time
periods (3 cases ≥40)
Tucker 1987 [14] US






Mean: 7 4 235 (64–602) All cases observed among females
2b. Mortality SMR, 95% CI SMR by treatment for
retinoblastoma




1092 1-yr survivors Median: 29 31 329 (223–467) Any Radiation 395 (268–560) AER=10.9; SMR is higher for women
vs men (not statistically significant)











*Deaths observed up to ≥50 years
after RB *SMR peaks at 20–29 years
but SMRs significantly elevated in all
time periods




408 Median: 12 6 453 (203.5 - 1008) NA
Fletcher 2004 [10] UK Patients




144 25-yr survivors Median attained
age: 60; Follow-up
began in 1940
4 110 (29–281) NA *Treatment not available, but radiation
was not typically used during these
years of Rb diagnosis



















LMS [25], which may confer an increased susceptibility
to this tumor in this population. LMS of other pelvic
sites have also been reported after Rb [26], and there
have been several case reports of LMS diagnosed in the
bladder [27,28].
Very high risks have also been observed for fibrosarco-
mas, rhabdomyosarcomas and pleomorphic sarcomas
within the first 10 years after Rb [22,29]. These histo-
logic types comprised the majority of STS that were
diagnosed in or near the field of radiation, in contrast to
LMS, which were more likely to occur outside the radi-
ation field (Table 3). Only 10% of rhabdomyosarcomas
arise in the soft tissue of the head, neck or face in the
general population, whereas all of the rhabdomyosarco-
mas arose in the head following radiation for Rb [22].
An increased risk for liposarcomas that began 10 years
after diagnosis of hereditary Rb was observed in the
study by Kleinerman et al. [22]. Lipomas, a benign
tumor of fat tissue, have also been reported to be
increased in that cohort, and the investigators noted a
possible association between lipomas and subsequent
risk of a soft tissue sarcoma [30]. Following this observa-
tion, a RB1 mutation was identified in lipomas from her-
editary Rb patients [31,32].
It has been suggested that females may be at higher
risk of STS after hereditary Rb [9], but studies of Rb
survivors have not consistently reported a higher risk
among females. Males have a higher rate of Rb in the
general population and all liposarcomas and lipomas
occurred in males in the cohort in which they were
evaluated [22,30].
Treatment for Rb and risk of STS
Although both radiotherapy and chemotherapy for heredi-
tary Rb have been associated with an increased risk for
STS, the evidence is more consistent for radiotherapy.
(For a detailed review of radiation-related sarcoma, see
Berrington de Gonzalez et al. in this issue). Wong et al.
demonstrated a radiation dose–response for STS whereby
risk increased with dose up to a significant 11-fold
increased risk at ≥60 Gy [11]. The risk for STS was not
associated with increasing alkylating agent score in the
same cohort [22], whereas in another study of STS after
all types of pediatric malignancies, including Rb, the risk
for STS increased significantly with cumulative dose of al-
kylating agents, adjusted for radiation exposure [15].
Increased risks of STS have also been noted following sur-
gery only for hereditary Rb [6,10].
Molecular evidence for an association of sarcomas
with RB1
In additional to the epidemiologic evidence of an excess
risk for both bone and STS in hereditary Rb patients,
structural alterations of the RB1 gene are well documen-
ted in primary bone sarcomas [33] and soft tissue sarco-
mas [34-36]. Most of the bone and soft tissue sarcomas
diagnosed in hereditary Rb patients have complex karyo-
types, including fibrosarcoma, LMS, pleomorphic sarcoma,
liposarcoma and osteosarcoma that are all related to inher-
ited defects in the RB pathway [37]. A comprehensive re-
view by Burkhart and Sage of cellular mechanisms of
tumor suppression by the retinoblastoma gene discusses
the loss of RB1 function and cancer progression [2].
Conclusion
Hereditary Rb patients are at significant risk of develop-
ing a sarcoma due to past radiation treatment and gen-
etic susceptibility. Sarcomas account for approximately
40% to 60% of second cancers in hereditary Rb survivors.
There is convincing epidemiologic evidence linking past
radiotherapy with sarcomas in hereditary patients. Risk
of bone and STS begins within 10 years of treatment for
hereditary Rb and continues throughout adulthood,
most notably for STS.
Recognition of the increased risk for sarcomas asso-
ciated with past radiotherapy has influenced the current
treatment of retinoblastoma with a trend towards greater
use of chemotherapy, focal therapies, and most recently,
chemosurgery [38-40]. In addition, guidelines for im-
aging children for pre-treatment diagnostic evaluation of
Rb without the use of ionizing radiation have been
recommended to reduce the risk of second cancers in
Rb patients [41]. However, the risk for bone sarcomas
and STS remains, reflecting the genetic predisposition to
these sarcomas due to loss of heterozygosity in the RB1
gene. Patients who were treated in 1960s and 1970s with
radiotherapy are still at risk in their adult years for the
development of STS. Given the excellent survival of
most retinoblastoma patients, it is important for survi-
vors, their families and health care providers to be aware
of these risks, especially for hereditary patients [42].
There is on-going research to try to identify whether
specific RB1 mutations or location of mutations predis-
pose to sarcomas, which could lead to identification of
those survivors at greatest risk [43]. The development of
Table 3 Location of soft tissue sarcoma after
radiotherapy for retinoblastoma*
STS subtype In-field Out-of-field Total
Leiomyosarcoma 8 (38.1) 13 (61.9) 21 (100.)
Fibrosarcoma 13 (100.) 0 13 (100.)
Pleomorphic sarcoma 11 (100.) 0 11 (100.)
Rhabdomyosarcoma 7 (100.) 0 7 (100.)
Liposarcoma 1 (33.3) 2 (66.7) 3 (100.)
Other STS 8 (80.0) 2 (20.0) 10 (100.)
Total 48 (72.7) 18 (27.3) 66 (100.)
*Based on data from Kleinerman et al. [22].
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comprehensive guidelines for long-term follow-up that
are specifically tailored for detection of sarcomas and
other second primary cancers in retinoblastoma survi-
vors are also needed, especially for those patients who
received radiotherapy in the past.
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